Epidemiologic and imaging studies link visceral adiposity, body composition, and adipose-related mediators such as leptin and IL-6 with subclinical interstitial abnormalities and outcomes in fibrotic ILD, while genetic and clinical data support a context-dependent protective role for adiponectin signaling. Here, IL6 is linked to interstitial lung disease.